Article Text

This article has a correction. Please see:

PDF
▼ Indacaterol for COPD

Abstract

▼Indacaterol powder for inhalation (Onbrez Breezhaler – Novartis) is a long-acting beta2 agonist, licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). In this article, we consider the evidence for indacaterol and how its use fits with current management strategies for COPD.

Statistics from Altmetric.com

  • Relevant BNF section: BNF 3.1.1.1

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • Correction
      BMJ Publishing Group Ltd